KYNB Kyntra Bio Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: KYNB

Price (delayed)

$7.25

Market cap

$29.36M

P/E Ratio

0.16

Dividend/share

N/A

EPS

$45.28

Enterprise value

$49.21M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 40

FibroGen, Inc. is a biopharmaceutical company focused on accelerating the development of novel therapies at the frontiers of cancer biology. Roxadustat (爱瑞卓 ®, EVRENZO™) is currently approved in China, Europe, ...

Highlights
KYNB's equity has surged by 86% year-on-year and by 31% since the previous quarter
The stock's price to earnings (P/E) is 20% less than its last 4 quarters average of 0.2
The company's debt fell by 48% YoY but it rose by 4.6% QoQ
KYNB's gross profit has dropped by 98% year-on-year and by 90% since the previous quarter
The gross margin has plunged by 96% YoY and by 85% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.fibrogen.com
Peers: ILMN A HBIO PACB

Key stats

What are the main financial stats of KYNB

KYNB stock price

How has the Kyntra Bio stock price performed over time
Intraday
-0.41%
1 week
-4.73%
1 month
-3.59%
1 year
-39.43%
YTD
-17.43%
QTD
-3.97%

Financial performance

How have Kyntra Bio's revenue and profit performed over time
Revenue
$4.62M
Gross profit
$289,000
Operating income
-$50.32M
Net income
$183.19M
Gross margin
6.3%
Net margin
3,967.8%
KYNB's gross profit has dropped by 98% year-on-year and by 90% since the previous quarter
The gross margin has plunged by 96% YoY and by 85% from the previous quarter
Kyntra Bio's operating margin has plunged by 81% from the previous quarter but it has increased by 2.1% YoY
The company's net margin has surged by 80% QoQ

Price vs fundamentals

How does KYNB's price correlate with its fundamentals

Growth

What is Kyntra Bio's growth rate over time

Valuation

What is Kyntra Bio stock price valuation
P/E
0.16
P/B
N/A
P/S
6.36
EV/EBIT
0.26
EV/EBITDA
0.26
EV/Sales
10.66
The stock's price to earnings (P/E) is 20% less than its last 4 quarters average of 0.2
The company's EPS rose by 12% QoQ
KYNB's equity has surged by 86% year-on-year and by 31% since the previous quarter
The company's revenue fell by 38% QoQ and by 37% YoY
The stock's price to sales (P/S) is 20% more than its 5-year quarterly average of 5.3 and 18% more than its last 4 quarters average of 5.4

Efficiency

How efficient is Kyntra Bio business performance
The company's return on sales has surged by 80% QoQ
KYNB's return on assets is up by 30% since the previous quarter
KYNB's return on invested capital is up by 27% since the previous quarter

Dividends

What is KYNB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KYNB.

Financial health

How did Kyntra Bio financials performed over time
KYNB's total assets is 7% smaller than its total liabilities
KYNB's current ratio has surged by 159% year-on-year but it is down by 25% since the previous quarter
Kyntra Bio's total liabilities has plunged by 70% YoY and by 8% from the previous quarter
KYNB's equity has surged by 86% year-on-year and by 31% since the previous quarter
KYNB's debt to equity has plunged by 52% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.